Selank is a synthetic heptapeptide developed in Russia with well-documented anxiolytic and nootropic effects. Unlike benzodiazepines, it calms without sedation or dependence —…
Anxiety and cognitive performance are usually treated as separate problems with separate solutions: therapy and SSRIs for one, nootropics and stimulants for the other. Selank challenges that assumption. Originally developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, this synthetic peptide has been formally approved as an anxiolytic medication in Russia and Ukraine — while simultaneously earning a reputation as a nootropic.
Selank (also written as Selanc) is a heptapeptide — a chain of seven amino acids. It's a synthetic analog of the endogenous human protein tuftsin, which plays a role in immune modulation and neurological function. Researchers at the Russian Academy modified tuftsin's structure to increase stability and add anxiolytic properties.
Unlike many anxiety medications, Selank is not a benzodiazepine and doesn't work on the GABA-A receptor in the same way. This distinction is important: it means it lacks the sedation, cognitive dulling, and physical dependence risk that characterize BZDs.
Selank's effects emerge from several overlapping mechanisms:
GABAergic Modulation. Selank appears to modulate the GABA system — the primary inhibitory neurotransmitter system in the brain — but through regulatory pathways rather than direct receptor agonism. This produces an anxiolytic effect without the receptor downregulation that leads to tolerance with benzodiazepines.
BDNF Upregulation. Studies have shown Selank increases brain-derived neurotrophic factor (BDNF), a key protein involved in neuroplasticity, memory formation, and neuronal survival. BDNF deficiency is implicated in depression, anxiety, and cognitive decline.
Enkephalin Stability. Selank inhibits the enzymes that break down enkephalins — endogenous peptides that contribute to mood regulation and pain modulation. Higher enkephalin activity is associated with reduced anxiety and improved emotional stability.
Serotonin Modulation. Research in animal models has found Selank influences serotonin metabolism in a dose-dependent manner, potentially contributing to its mood-stabilizing effects without the delayed onset of SSRI-class medications.
Russian clinical trials conducted from the 1990s through the 2010s evaluated Selank in patients with generalized anxiety disorder (GAD) and neurasthenia. Results showed significant reductions in anxiety scores (using the Hamilton Anxiety Scale) with an onset of effect within the first few days of use — notably faster than SSRIs, which typically require 4-6 weeks.
In one comparative trial, Selank performed comparably to the benzodiazepine medazepam for anxiety reduction, but without the sedation, memory impairment, or withdrawal effects associated with the BZD. Patients on Selank also reported improvements in attention, learning, and memory — effects rarely seen with sedating anxiolytics.
Animal studies have added mechanistic detail: Selank has demonstrated improvements in maze-learning tasks, reduced anxiety-related behavior in models of stress, and neuroprotective effects against oxidative stress.
Selank is typically administered intranasally — a few drops of solution in each nostril — or subcutaneously. Intranasal delivery bypasses first-pass metabolism and allows for rapid CNS uptake across the blood-brain barrier.
Common dosing is 250–750 mcg per day, split into 1-2 doses. Many users report benefits within the first week. Cycle lengths of 10–14 days are often recommended, with breaks of equal length, though longer courses have been used clinically in Russia.
It's worth noting: Selank degrades rapidly at room temperature. Proper storage (refrigeration, protection from light) is essential to maintain potency.
Selank has a notably clean safety record from the Russian clinical trials — no significant adverse effects, no dependence, no withdrawal syndrome reported. It does not appear to impair cognitive performance or psychomotor function at therapeutic doses.
As with most research peptides outside Russia, it lacks FDA approval. Sourcing from reputable, third-party-tested suppliers is critical.
Selank occupies a rare niche: an anxiolytic that doesn't dull the mind and a nootropic that doesn't amp up anxiety. For people dealing with stress-driven cognitive fog or anxiety that doesn't warrant pharmaceutical intervention, it represents a compelling option with a real research base — even if that research mostly comes from one country's medical establishment. The mechanism is sound, the clinical data is reasonably solid, and the side effect profile is minimal.
Put this into practice
Don’t just read about better habits. Build them into your day.
HabitForge turns ideas like this into a daily system with check-ins, reflection, and recovery cues that help you keep going when life gets messy.
Next step
Want to make this easier to do every day?
HabitForge turns these ideas into a calm daily system with check-ins, reflection, and recovery cues that help you keep momentum when life gets noisy.
See the appKeep reading
Individual peptides target specific pathways — stacking them intelligently can produce synergistic effects for recovery, body composition, and cognitive performance. Here's a…
SS-31 (elamipretide) is a small synthetic peptide that targets the inner mitochondrial membrane, protecting cardiolipin and restoring mitochondrial function. It's one of the…
PT-141, also known as bremelanotide, is a melanocortin receptor agonist that works through the central nervous system to enhance sexual desire in both men and women. Here's…